Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Other Non Operating Income (2020 - 2025)

Caribou Biosciences has reported Other Non Operating Income over the past 6 years, most recently at $2.2 million for Q4 2025.

  • Quarterly Other Non Operating Income fell 58.57% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.8 million through Dec 2025, down 49.57% year-over-year, with the annual reading at $8.8 million for FY2025, 49.57% down from the prior year.
  • Other Non Operating Income was $2.2 million for Q4 2025 at Caribou Biosciences, up from $1.9 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $5.3 million in Q4 2024 and troughed at $16000.0 in Q1 2021.
  • The 5-year median for Other Non Operating Income is $2.3 million (2022), against an average of $2.5 million.
  • Year-over-year, Other Non Operating Income crashed 78.9% in 2021 and then soared 3157.78% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at $45000.0 in 2021, then surged by 5080.0% to $2.3 million in 2022, then skyrocketed by 106.61% to $4.8 million in 2023, then rose by 10.26% to $5.3 million in 2024, then plummeted by 58.57% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Other Non Operating Income are $2.2 million (Q4 2025), $1.9 million (Q3 2025), and $2.2 million (Q2 2025).